Drug Information

Drug General Information
Drug ID
D0T5QT
Former ID
DAP000028
Drug Name
Becaplermin
Synonyms
Regranex; Regranex (TN); Becaplermin (USAN/INN)
Indication Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] Approved [536297]
Therapeutic Class
Antiulcer Agents
Company
Ortho-McNeil Pharmaceutical
Formula
C532H892N162O153S9
CAS Number
CAS 165101-51-9
PubChem Substance ID
17397220
SuperDrug ATC ID
A01AD08; D03AX06
Target and Pathway
Target(s) Beta platelet-derived growth factor receptor Target Info Modulator [556264]
KEGG Pathway MAPK signaling pathway
Ras signaling pathway
Rap1 signaling pathway
Calcium signaling pathway
Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Focal adhesion
Gap junction
Regulation of actin cytoskeleton
HTLV-I infection
Pathways in cancer
MicroRNAs in cancer
Glioma
Prostate cancer
Melanoma
Central carbon metabolism in cancer
Choline metabolism in cancer
PANTHER Pathway Angiogenesis
PDGF signaling pathway
Pathway Interaction Database Signaling events mediated by PTP1B
Beta3 integrin cell surface interactions
S1P3 pathway
Nectin adhesion pathway
Signaling events mediated by TCPTP
SHP2 signaling
S1P1 pathway
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
PDGFR-beta signaling pathway
Validated targets of C-MYC transcriptional repression
PDGF receptor signaling network
Reactome PIP3 activates AKT signaling
Constitutive Signaling by Aberrant PI3K in Cancer
RAF/MAP kinase cascade
WikiPathways Regulation of Actin Cytoskeleton
MAPK Signaling Pathway
Osteoblast Signaling
Focal Adhesion
PIP3 activates AKT signaling
PDGF Pathway
Signaling Pathways in Glioblastoma
Signaling by PDGF
References
Ref 536297Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.